Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 13/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8094732 | 0.92 | CES1 (0.52) | CES1CES2LPAR1LPAR3 | |
| SCHEMBL9408565 | 0.90 | CES1 (0.55) | CES1CES2LPAR1LPAR3 | |
| SCHEMBL2616357 | 0.78 | CES1 (0.39) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL27955697 | 0.78 | FDPS (0.39) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL7858317 | 0.77 | — | — | |
| SCHEMBL2349836 | 0.77 | ESR1 (0.39) | CES2ESR1ESR2 | |
| SCHEMBL9815221 | 0.77 | — | — | |
| SCHEMBL13474588 | 0.76 | CES1 (0.38) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL30156510 | 0.76 | CES1 (0.38) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL25948178 | 0.76 | CES1 (0.38) | CES1CES2LPAR1LPAR3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-7932280-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | CES1 3248/4885CES2 4734/4885LPAR1 2855/4885 |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CES1 22/4885CES2 305/4885LPAR1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.